N-Zyme Biomedical
PrivateLast Round
Series A
Jul 22, 2026
Total Funding Raised
$4.6M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
N-Zyme Biomedical is a clinical-stage biotechnology company developing first-in-class therapies targeting pepsin to treat laryngopharyngeal reflux and gastroesophageal reflux disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
N-Zyme Biomedical Comparables
Compare N-Zyme Biomedical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ellodi Pharmaceuticals | 68% | |
| Phathom Pharmaceuticals | 66% | |
| ThirtyFiveBio | 60% | |
N-Zyme Biomedical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 22, 2026 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 76% MoM, reaching 4.8K.
- Jul 22, 2026
$5M round completed.
N-Zyme Biomedical Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about N-Zyme Biomedical's valuation, stock price, and market status.